ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Roschewski Discusses DA-EPOCH-R in Burkitt Lymphoma

Mark J. Roschewski, MD
Published: Thursday, Jul 19, 2018



Mark J. Roschewski, MD, staff clinician, associate research clinician, clinical director, Malignancies Branch of the Center for Cancer Research, National Cancer Institute, discusses dose-adjusted infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (Rituxan; DA-EPOCH-R) in adult patients with Burkitt lymphoma.

Burkitt lymphoma is rarely found in adults, and treatment-related toxicities are a significant barrier to treatment. The current standard of care for these patients is an intensive regimen of chemotherapy.

An NCI study investigated DA-EPOCH-R in patients with Burkitt lymphoma. The primary endpoint was event-free survival (EFS), with secondary objections of progression-free survival, time to progression, overall survival and predictive ability of PET after 2 cycles. All stages of Burkitt lymphoma were allowed, regardless of HIV status, says Roschewski.

Results showed that DA-EPOCH-R is effective in adults of all ages, with a favorable 3-year EFS compared to intensive regimens, and a low rate of central nervous system failure. Additionally, Roschewski notes that all 14 patients with low-risk Burkitt lymphoma on this study were cured.


Mark J. Roschewski, MD, staff clinician, associate research clinician, clinical director, Malignancies Branch of the Center for Cancer Research, National Cancer Institute, discusses dose-adjusted infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (Rituxan; DA-EPOCH-R) in adult patients with Burkitt lymphoma.

Burkitt lymphoma is rarely found in adults, and treatment-related toxicities are a significant barrier to treatment. The current standard of care for these patients is an intensive regimen of chemotherapy.

An NCI study investigated DA-EPOCH-R in patients with Burkitt lymphoma. The primary endpoint was event-free survival (EFS), with secondary objections of progression-free survival, time to progression, overall survival and predictive ability of PET after 2 cycles. All stages of Burkitt lymphoma were allowed, regardless of HIV status, says Roschewski.

Results showed that DA-EPOCH-R is effective in adults of all ages, with a favorable 3-year EFS compared to intensive regimens, and a low rate of central nervous system failure. Additionally, Roschewski notes that all 14 patients with low-risk Burkitt lymphoma on this study were cured.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x